Skip to main content

Advertisement

SpringerLink
Log in

Predominance of IgG1 and IgG3 subclasses of autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Analysis of IgG subclass distribution of antibodies may provide insights into the mechanisms driving antibody production. Here, we have first determined IgG subclass distribution of anti-recombinant peptidylarginine deiminase 4 (anti-hPADI4) antibodies in sera from patients with rheumatoid arthritis (RA). Sera from 103 RA patients were screened to IgG anti-PADI4 using recombinant antigens. For positive samples, the subclass distribution of IgG anti-hPADI4 was determined by means of establishing the equipotency of four HRP-labeled IgG subclass-specific monoclonal antibodies. The subclass profiles were compared among individuals with different disease status. Thirty-three out of 103 RA patients were determined as IgG anti-hPADI4-positive. As expressed by percentage levels to total IgG anti-hPADI4 activity, IgG1 and IgG3 were determined to be the predominant subclasses of anti-hPADI4. Furthermore, distinct subclass distribution patterns were observed in patients with different disease status. The IgG subclass distribution of anti-hPADI4 indicates that a leading T lymphocyte-regulated IgG1 and IgG3 responses may contribute to a better understanding of the role of anti-PADI4 in RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

Fc:

Crystallized fragment

RA:

Rheumatoid arthritis

PADI4:

Peptidylarginine deiminase 4

IgG:

Immunoglobulin G

ACPA:

Anti-citrullinated protein autoantibodies

anti-hPADI4:

Autoantibodies against recombinant PADI4

DAS28:

Disease active score in 28 swollen and 28 tender joints

DMARDs:

Disease-modifying anti-rheumatic drugs

SLE:

Systemic lupus erythematosus

pSS:

Primary Sjögren syndrome

SSc:

Systemic sclerosis

AU:

Arbitrary unit

HRP:

Horseradish peroxidase

ELISA:

Enzyme-linked immunosorbent assay

PBS:

Phosphate-buffered saline

PBST:

PBS with 0.05% Tween-20

NCS:

Newborn calf serum

RT:

Room temperature

Th1/2:

T helper cell 1/2

Sm:

Smith antigen

U1-RNP:

U1 small nuclear ribonucleoprotein

ADCC:

Antibody-dependent cell-mediated cytotoxicity

RF:

Rheumatoid factor

References

  1. Suzuki A, Yamada R, Yamamoto K (2007) Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann NY Acad Sci 1108:323–339

    Article  PubMed  CAS  Google Scholar 

  2. Klareskog L, Widhe M, Hermansson M, Rönnelid J (2008) Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol 20:300–305

    Article  PubMed  CAS  Google Scholar 

  3. Takizawa Y, Sawada T, Suzuki A, Yamada R, Inoue T, Yamamoto K (2005) Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. Scand J Rheumatol 34:212–215

    Article  PubMed  CAS  Google Scholar 

  4. Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewé R, Ødegård S, Kvien TK, Molberg Ø (2008) Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis 67:414–417

    Article  PubMed  CAS  Google Scholar 

  5. Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg Ø (2009) Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents. Ann Rheum Dis 68:249–252

    Article  PubMed  CAS  Google Scholar 

  6. Zhao J, Zhao Y, He J, Jia R, Li Z (2008) Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol 35:969–974

    PubMed  CAS  Google Scholar 

  7. Harris ML, Darrah E, Lam GK et al (2008) Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 58:1958–1967

    Article  PubMed  CAS  Google Scholar 

  8. Auger I, Balandraud N, Rak J, Lambert N, Martin M, Roudier J (2009) New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis 68:591–594

    Article  PubMed  CAS  Google Scholar 

  9. Arnett FC, Edworthy SM, Bloch DA (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  PubMed  CAS  Google Scholar 

  10. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850

    Article  PubMed  Google Scholar 

  11. Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatol Oxf 43:1252–1255

    Article  CAS  Google Scholar 

  12. Samarkos M, Davies KA, Gordon C, Walport MJ, Loizou S (2001) IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology Oxf 40:1026–1032

    Article  CAS  Google Scholar 

  13. Hamilton RG (1987) Human IgG subclass measurements in the clinical laboratory. Clin Chem 33:1707–1725

    PubMed  CAS  Google Scholar 

  14. Rubin RL, Tang FL, Chan EK, Pollard KM, Tsay G, Tan EM (1986) IgG subclasses of autoantibodies in systemic lupus erythematosus, Sjogren’s syndrome, and drug-induced autoimmunity. J Immunol 137:2528–2534

    PubMed  CAS  Google Scholar 

  15. Tokano Y, Yasuma M, Harada S, Takasaki Y, Hashimoto H, Okumura K, Hirose S (1991) Clinical significance of IgG subclasses of Anti-Sm and U1 ribonucleoprotein antibodies in patients with systemic lupus erythematosus and mixed connective tissue disease. J Clin Immunol 11:317–325

    Article  PubMed  CAS  Google Scholar 

  16. Koga M, Yuki N, Hirata K, Morimatsu M, Mori M, Kuwabara S (2003) Anti-GM1 antibody IgG subclass: a clinical recovery predictor in Guillain–Barré syndrome. Neurology 60:1514–1518

    PubMed  CAS  Google Scholar 

  17. de Haan S, Lahooti H, Morris O, Wall JR (2010) Epitopes, immunoglobulin classes and immunoglobulin G subclasses of calsequestrin antibodies in patients with thyroid eye disease. Autoimmunity. doi:10.3109/08916931003774954

    PubMed  Google Scholar 

  18. Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S, Yamamoto K (2005) Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatol Oxf 44:40–50

    Article  CAS  Google Scholar 

  19. Foulquier C, Sebbag M, Clavel C et al (2007) Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 56:3541–3553

    Article  PubMed  CAS  Google Scholar 

  20. Spiegelberg HL (1989) Biological role of different antibody classes. Int Arch Allergy Appl Immunol 90(Suppl 1):22–27

    Article  PubMed  CAS  Google Scholar 

  21. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356–361

    Article  PubMed  CAS  Google Scholar 

  22. Cohen PL, Cheek RL, Hadler JA, Yount WJ, Eisenberg RA (1987) The subclass distribution of human IgG rheumatoid factor. J Immunol 139:1466–1471

    PubMed  CAS  Google Scholar 

  23. Chapuy-Regaud S, Nogueira L, Clavel C, Sebbag M, Vincent C, Serre G (2005) IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol 139:542–550

    Article  PubMed  CAS  Google Scholar 

  24. Engelmann R, Brandt J, Eggert M, Karberg K, Krause A, Neeck G, Mueller-Hilke B (2008) IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA. Rheumatol Oxf 47:1489–1492

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Akari Suzuki (Laboratory for Rheumatic Diseases, SNP Research Centre, Institute of Physical and Chemical Research, Kanagawa, Japan) for offering the PADI4 expression vector.

Funding

The current study did not receive any external funding.

Disclosures

None.

Author information

Authors and Affiliations

  1. Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China

    Wei Wang

  2. National Center for Clinical Laboratories, Beijing Hospital, No.1 Dahua Road, Dongdan, Beijing, 100730, People’s Republic of China

    Wei Wang & Jinming Li

Authors
  1. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinming Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jinming Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, W., Li, J. Predominance of IgG1 and IgG3 subclasses of autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis. Clin Rheumatol 30, 563–567 (2011). https://doi.org/10.1007/s10067-010-1671-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-010-1671-4

Keywords

Search

Navigation